GuidelineBritish journal of cancer2005
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
Guideline in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05384535 (Utility of Biparametric MRI), which is not on this map. Cited by 174 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
Who cites it
174 citing papers in PubMed.
- Trial
- Trial
- A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.BMC cancer · 2016Trial
- Assessment of Progression-Free-Survival in Glioblastomas by Intratreatment Dynamic Contrast-Enhanced MRI.Clinical neuroradiology · 2016Trial
- MR imaging in hepatocellular carcinoma: correlations between MRI features and molecular marker VEGF.Medical oncology (Northwood, London, England) · 2014Trial
- Trial
- Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.British journal of cancer · 2012Trial
- ¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer.European journal of nuclear medicine and molecular imaging · 2011Trial
- Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Trial
- Inter-Vendor Variability of Perfusion Parameters Derived from Dynamic Contrast-Enhanced MRI in Patients with Prostate Cancer.Tomography (Ann Arbor, Mich.) · 2026Article
- Dynamic Contrast Enhanced-Magnetic Resonance Fingerprinting (DCE-MRF) Improves Detection of Induced Vascular Perfusion Reduction in a Mouse Breast Cancer Model.Magnetic resonance in medicine · 2026Article
- Dopamine D2 Receptor Agonists as Modulators of VEGF-A-Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Hepatocellular Carcinoma: A Review of Emerging Applications for Locoregional Therapy.Bioengineering (Basel, Switzerland) · 2025Review
- Article
- Article
- PDZK1 is correlated with DCE-MRI perfusion parameters in high-grade glioma.Clinics (Sao Paulo, Brazil) · 2024Article
- Correlation of Perfusion Metrics with Ki-67 Proliferation Index and Axillary Involvement as a Prognostic Marker in Breast Carcinoma Cases: A Dynamic Contrast-Enhanced Perfusion MRI Study.Diagnostics (Basel, Switzerland) · 2023Article
- A Review on the Use of Imaging Biomarkers in Oncology Clinical Trials: Quality Assurance Strategies for Technical Validation.Tomography (Ann Arbor, Mich.) · 2023Review
- Article
- Article
114 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.